ECSP13012755A - Composiciones farmacéuticas que contienen un inhibidor de dgat1 - Google Patents

Composiciones farmacéuticas que contienen un inhibidor de dgat1

Info

Publication number
ECSP13012755A
ECSP13012755A ECSP13012755A ECSP13012755A EC SP13012755 A ECSP13012755 A EC SP13012755A EC SP13012755 A ECSP13012755 A EC SP13012755A EC SP13012755 A ECSP13012755 A EC SP13012755A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
compositions containing
dgat1 inhibitor
properties
dgat1
Prior art date
Application number
Other languages
English (en)
Inventor
Hong Wen
Natrajan Kumaraperumal
Richard Nause
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44908106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012755(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP13012755A publication Critical patent/ECSP13012755A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica, la cual comprende: a) una cantidad terapéuticamente efectiva de un compuesto de la fórmula (I), o de una sal farmacéuticamente aceptable del mismo, b) uno o más, por ejemplo 1, 2 ó 3, tensoactivos con propiedades lubricantes; c) uno o más, por ejemplo 1, 2 ó 3, aglutinantes secos con propiedades desintegrantes; d) uno o más, por ejemplo 1, 2 ó 3, rellenos, y e) uno o más, por ejemplo 1, 2 ó 3, desintegrantes.
ECSP13012755 2010-10-14 2013-04-12 Composiciones farmacéuticas que contienen un inhibidor de dgat1 ECSP13012755A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39310310P 2010-10-14 2010-10-14

Publications (1)

Publication Number Publication Date
ECSP13012755A true ECSP13012755A (es) 2014-01-31

Family

ID=44908106

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012755 ECSP13012755A (es) 2010-10-14 2013-04-12 Composiciones farmacéuticas que contienen un inhibidor de dgat1

Country Status (29)

Country Link
US (5) US20130190354A1 (es)
EP (1) EP2627319B1 (es)
JP (1) JP6060081B2 (es)
KR (1) KR20130100311A (es)
CN (1) CN103179957B (es)
AR (1) AR083417A1 (es)
AU (1) AU2011316003B2 (es)
BR (1) BR112013008757A2 (es)
CA (1) CA2813781C (es)
CL (1) CL2013001001A1 (es)
CO (1) CO6710915A2 (es)
DK (1) DK2627319T3 (es)
EC (1) ECSP13012755A (es)
ES (1) ES2712064T3 (es)
GT (1) GT201300096A (es)
HU (1) HUE043524T2 (es)
IL (1) IL225434A0 (es)
MA (1) MA34599B1 (es)
MX (1) MX2013004162A (es)
NZ (1) NZ608558A (es)
PE (1) PE20140375A1 (es)
PL (1) PL2627319T3 (es)
PT (1) PT2627319T (es)
RU (1) RU2595866C2 (es)
SG (1) SG189078A1 (es)
SI (1) SI2627319T1 (es)
TR (1) TR201902435T4 (es)
WO (1) WO2012051488A1 (es)
ZA (1) ZA201302108B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9108956B2 (en) * 2012-04-27 2015-08-18 Novartis Ag Cyclic ether DGAT1 inhibitorscyclic ether DGAT1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2978204A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
JP2018534323A (ja) 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
MX2020009604A (es) * 2018-03-16 2023-01-25 Anji Pharmaceuticals Inc Composiciones y metodos para tratar el estre?imiento grave.
EP3769765B1 (en) * 2018-03-19 2024-04-17 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2235707A1 (en) 1995-11-14 1997-05-22 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19816070A1 (de) * 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
CN1668282A (zh) * 2001-12-21 2005-09-14 辉瑞产品公司 可直接压制的阿齐霉素配方
AU2006236155A1 (en) * 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
KR101219042B1 (ko) * 2005-12-06 2013-01-07 삼성디스플레이 주식회사 반투과형 액정 표시 장치
JP5165582B2 (ja) * 2005-12-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
MX2008011459A (es) * 2006-03-06 2008-09-24 Wyeth Corp Formulaciones y procesos para tabletas.
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
ES2589736T3 (es) * 2006-03-31 2016-11-16 Novartis Ag Derivados de piridina como inhibidores de DGAT
MX2009005691A (es) 2006-11-29 2009-08-07 Abbott Lab Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
US20080145425A1 (en) * 2006-12-15 2008-06-19 Pliva Research & Development Limited Pharmaceutical composition of zolpidem
NZ580660A (en) 2007-04-30 2012-02-24 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US8283331B2 (en) * 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
SI3222277T1 (sl) * 2009-03-31 2021-02-26 Ligand Pharmaceuticals Inc. Bifenilsulfonamidni antagonist receptorja endotelina in angiotensina II za zdravljenje glomeruloskleroze in z IgA povzročene nefropatije
KR20130073884A (ko) * 2010-03-30 2013-07-03 노파르티스 아게 Ｄｇａｔ1 억제제의 용도
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor

Also Published As

Publication number Publication date
NZ608558A (en) 2015-03-27
JP2013539794A (ja) 2013-10-28
AU2011316003A1 (en) 2013-04-11
CO6710915A2 (es) 2013-07-15
KR20130100311A (ko) 2013-09-10
RU2595866C2 (ru) 2016-08-27
US20160374947A1 (en) 2016-12-29
CL2013001001A1 (es) 2013-10-25
US20130190354A1 (en) 2013-07-25
MX2013004162A (es) 2014-12-08
MA34599B1 (fr) 2013-10-02
US20150320687A1 (en) 2015-11-12
RU2013121795A (ru) 2014-11-20
DK2627319T3 (en) 2019-03-18
US20180243222A1 (en) 2018-08-30
SI2627319T1 (sl) 2019-04-30
CN103179957B (zh) 2016-05-18
SG189078A1 (en) 2013-05-31
TR201902435T4 (tr) 2019-03-21
AU2011316003B2 (en) 2015-03-19
US11304907B2 (en) 2022-04-19
HUE043524T2 (hu) 2019-08-28
CN103179957A (zh) 2013-06-26
IL225434A0 (en) 2013-06-27
PT2627319T (pt) 2019-02-27
CA2813781C (en) 2018-08-07
US10646446B2 (en) 2020-05-12
EP2627319A1 (en) 2013-08-21
EP2627319B1 (en) 2018-11-21
ZA201302108B (en) 2013-11-27
GT201300096A (es) 2014-07-08
PE20140375A1 (es) 2014-03-19
WO2012051488A1 (en) 2012-04-19
AR083417A1 (es) 2013-02-21
BR112013008757A2 (pt) 2020-09-01
CA2813781A1 (en) 2012-04-19
ES2712064T3 (es) 2019-05-09
JP6060081B2 (ja) 2017-01-11
PL2627319T3 (pl) 2019-05-31
US20200230062A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
ECSP13012755A (es) Composiciones farmacéuticas que contienen un inhibidor de dgat1
UY32490A (es) Inhibidores de beta-secretasa
CR20140143A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY32730A (es) Inhibidores de cyp17
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
ECSP12012290A (es) Formulaciones farmacéuticas
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112013016595A2 (pt) inibidores de neprilisina
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
DOP2014000121A (es) Derivados de betulina
CO6501183A2 (es) Piperidinas sustituidas como antagonistas de ccr3
CR10479A (es) Modulares bencimidazolicos de vr1
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
GT200900179A (es) Derivados de isoquinolona sustituidos con cicloalquilamina
CR20140134A (es) Composiciones farmacéuticas
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
ECSP088965A (es) Derivados de 2-tioxantina que actúan como inhibidores de la mpo
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
EP2585455A4 (en) COMPOUNDS AND THEIR USE IN THE MODULATION OF THE CONCENTRATIONS OF VARIOUS AMYLOID BETA PEPTIDE ALLOYS
SG158091A1 (en) Imidazoazepinone compounds